Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Breast Cancer
Interventions: Lovaza-Omega 3 fatty acid capsules, Dietary fish (canned salmon, albacore); Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glioma
Interventions: High Dose Radiation, Temozolomide; Radiation · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Overweight, Binge Eating
Interventions: Interpersonal Psychotherapy, Health Education; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
Interventions: RO6870810, Venetoclax, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Duarte, California • Stanford, California • New York, New York + 1 more

Conditions: Hypertension, High Blood Pressure
Interventions: Text Message Reminder; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Surgery, Anesthesia
Interventions: Continuation of High Frequency Jet Ventilation (HFJV); Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Embolism Acute
Interventions: Anticoagulation, mechanical aspiration thrombectomy; Drug · Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 14 more

Conditions: Hypertension
Interventions: Mindfulness based stress reduction, Progressive Muscle Relaxation; Behavioral
Lead sponsor: Kent State University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Healthy
Interventions: LY3437943; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Leukemia
Interventions: etoposide, topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2001
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes
Interventions: Intensive Diabetes Case Management; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adenocarcinoma of the Prostate
Interventions: enzalutamide; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Posterior Cortical Atrophy
Interventions: HD-tDCS sessions, Sham HD-tDCS sessions, HD-tDCS sessions - Open-label (after randomized treatment); Device
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hematologic Malignancies
Interventions: Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension
Interventions: sildenafil; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Fluorouracil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more

Conditions: Acute Myelogenous Leukemia
Interventions: cytosine arabinoside (ara-C), daunomycin, interleukin-2; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation); Drug · Radiation
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 60
States / cities: Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more

Conditions: Diabetes, Heart Failure
Interventions: Metformin; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 30 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Conditions: Parkinson Disease
Interventions: GENUS device (Active Settings), GENUS device (Sham settings); Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 45 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Chronic Kidney Diseases, High Cholesterol
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Malignant Melanoma
Interventions: Interleukin-2, Temozolomide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region Project 1 - Epidemiology (ACHIEVE P1-EPI)

A Study of the Effect of Arterial Carbon Dioxide Tension on the Recovery of Spontaneous Respiration

Comparison of Two Pulmonary Embolism Treatments

Mindfulness Based Stress Reduction for High Blood Pressure

A Study of LY3437943 in Healthy Participants With a High Body Mass Index

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Intensive Case Diabetes Management (ICDM) to Prevent Readmission

Enzalutamide in Patients With High-risk Prostate Cancer

Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Sildenafil and Pulmonary Artery Pressure

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease

Evolocumab In Advanced Chronic Kidney Disease Trial

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma